Tesamorelin or Ipamorelin: Which peptide is better?

Whether tesamorelin or ipamorelin is better depends largely on the intended goal, as both peptides stimulate growth hormone pathways in different ways and have been studied in different research and clinical contexts [1–10]. In head-to-head comparisons Tesamorelin vs. Ipamorelin, Tesamorelin has significantly stronger clinical evidence in humans regarding the reduction of visceral abdominal fat and liver fat, particularly in individuals with HIV-associated lipodystrophy, whereas ipamorelin is more frequently discussed in peptide research as a support for natural pulsatile growth hormone release, regeneration, sleep, and improvement in body composition [1–6].

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), which means that it stimulates the pituitary gland to increase the body’s natural production of growth hormone (GH) [1,2]. It is an FDA-approved prescription medicine, used primarily to treat HIV-associated lipodystrophy. Clinical trials consistently show that tesamorelin can significantly reduce visceral abdominal fat, decrease hepatic fat and increase levels of insulin-like growth factor-1 (IGF-1) [3–6]. In a pooled analysis of phase III trials conducted by Falutz et al. (2010), tesamorelin reduced visceral fat by approximately 15% over 26 weeks, whilst remaining relatively well tolerated [3]. Stanley et al. (2019) also reported a significant reduction in hepatic fat in individuals with HIV-associated non-alcoholic fatty liver disease (NAFLD) [5].

Ipamorelin works through a distinct mechanism. It is classified as a Growth Hormone Releasing Peptide (GHRP) and a selective ghrelin receptor agonist, meaning it stimulates GH release by activating the ghrelin receptor pathway [7–10]. Ghrelin is sometimes referred to as the „hunger hormone” as it also impacts appetite and metabolism. Compared to older GHRPs, ipamorelin is considered more selective, appearing to have a lesser impact on cortisol and prolactin levels. Research suggests that ipamorelin may support pulsatile GH release while potentially aiding in muscle recovery, sleep quality, tissue repair, appetite regulation, and bone metabolism [7–10].

Comparing Tesamorelin vs. Ipamorelin, tesamorelin generally has significantly stronger clinical evidence in humans. Numerous randomised controlled trials involving hundreds of participants have analysed the effects of tesamorelin on visceral fat reduction, liver fat, metabolic markers and long-term safety [3–6]. In contrast, a significant portion of the literature concerning ipamorelin is based on animal studies, mechanistic studies, pharmacokinetic analyses or smaller clinical studies focusing primarily on GH release patterns rather than major metabolic outcomes [7–10].

Tesamorelin may be more suitable in situations relating to:

• reducing visceral abdominal fat
• HIV-related lipodystrophy
• Non-alcoholic fatty liver disease (NAFLD)
• clinically documented metabolic dysfunction
• research on reducing liver fat
• under strict medical supervision

Ipamorelin is more often discussed in the context of:

• supporting the natural pulsatile release of GH
• Sleep regeneration and improvement
• muscle regeneration and improved body composition
• peptide coupling protocols
• research on the ghrelin receptor signalling
• potentially lower risk of GH overstimulation

One of the main differences between tesamorelin and ipamorelin is their regulatory status and the quality of available scientific evidence. Tesamorelin is an approved pharmaceutical drug supported by standardised dosing protocols and extensive Phase III clinical trial data [1–6]. Ipamorelin, on the other hand, is primarily considered a research peptide and is not widely approved as a prescription medication for routine clinical use in many countries [7–10].

The two peptides also differ in their effects on GH physiology. Tesamorelin stimulates the GHRH receptor pathway, whereas ipamorelin activates the ghrelin receptors known as GHSR-1a [1,7]. Some research protocols combine GHRH analogues, such as CJC-1295, with ipamorelin, as both pathways may act synergistically to increase GH release while maintaining more natural pulsatile hormonal patterns [7–10].

The profile of adverse effects may also vary slightly. Studies on tesamorelin have often reported injection site reactions, mild oedema or water retention, joint discomfort, and occasional issues with glucose monitoring due to increased IGF-1 activity [3–6]. Ipamorelin is often described as relatively selective and may theoretically cause fewer cortisol-related adverse effects than older GHRPs, although high-quality long-term human safety data remain limited [7–10].

It should be emphasised that none of these peptides should be treated as a substitute for a healthy lifestyle including proper nutrition, physical activity, sleep, or appropriate treatment of hormonal and metabolic disorders. Individual responses can vary significantly depending on hormone levels, age, body composition, metabolic health, and coexisting conditions.

Generally speaking, current evidence suggests that tesamorelin is usually a stronger evidence-based option for visceral fat reduction and improving metabolic parameters, while ipamorelin is more commonly utilised in peptide research and discussions surrounding GH optimisation, recovery, and body composition support. Ultimately, the better choice depends on the specific medical, metabolic, or research objective.

Disclaimer

The content is for educational and scientific information purposes only and should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. Tesamorelin is a prescription medication requiring medical supervision, whereas ipamorelin is primarily researched as a research peptide. Peptides affecting growth hormone and IGF-1 pathways can interact with metabolic, hormonal, and cardiovascular functions, therefore they should only be used under the supervision of a qualified healthcare professional.

References

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548730/
2. PubChem. (2025). Tesamorelin Compound Summary. National Centre for Biotechnology Information, National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin
3. Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicentre, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
4. Falutz, J., Allas, S., Mamputu, J. C., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
5. Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Agyapong, G., Torriani, M., Chung, R. T., & Grinspoon, S. K. (2019). Effect of tesamorelin on non-alcoholic fatty liver disease in HIV-positive individuals: A randomised, double-blind, multicentre study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
6. Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomised clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
7. Johansen, P. B., Nowak, J., Skjaerbaek, C., Pedersen, S. B., Flyvbjerg, A., & Andreassen, T. T. (1999). Ipamorelin, a new growth hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106–113. https://doi.org/10.1054/ghir.1999.9998
8. Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/A:1018955126402
9. Johansen, P. B., Hansen, K. T., Andersen, J. V., & Johansen, N. L. (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica, 28(11), 1083–1092. https://doi.org/10.1080/004982598238976
10. Jiménez-Reina, L., Cañete, R., de la Torre, M. J., & Bernal, G. (2002). Effect of chronic treatment with the growth hormone secretagogue ipamorelin in young female rats: In vitro somatotropic response. Histology and Histopathology, 17(3), 707–714. https://doi.org/10.14670/HH-17.707